Clinical trials: Cancer Disease Progression
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous…
- Trial name
- NCT07024173
- Testing
- HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets
- Where
- 2 sites in China
- Volunteers
- 240 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Colorectal Cancer
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.
- Trial name
- NCT06441565
- Testing
- Fruquintinib, Fluorouracil, Oxaliplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Adult
HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy
Primary objective: To evaluate the progression-free survival (PFS) for EOC202 combined with albumin-bound paclitaxel versus albumin-bound paclitaxel alone in treatment of the patients with HR positive, HER2 negative advanced…
- Trial name
- NCT05322720
- Testing
- EOC202, albumin-bound paclitaxel
- Volunteers
- 50 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal HPV Squamous Cell Carcinoma
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer
This prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance…
- Trial name
- NCT07407205
- Testing
- Concurrent Chemoradiotherapy, Dynamic Contrast-Enhanced MRI Perfusion (DCE-MRI)
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Stomach Neoplasms, Gastric Adenocarcinoma
Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia
Metastatic gastric cancer has a poor prognosis, and the cumulative toxicity of first-line platinum and fluoropyrimidine chemotherapy limits how long treatment can be continued.
- Conditions
- Stomach Neoplasms, Gastric Adenocarcinoma, Metastatic Gastric Cancer
- Trial name
- NCT07856212
- Testing
- Fluoropyrimidine Maintenance Therapy, Immune Checkpoint Inhibitor Maintenance, Targeted Therapy Maintenance
- Where
- 4 sites in Colombia
- Volunteers
- 150 people
- Sponsor
- Fundación Santa Fe de Bogota
Metastatic Brain Tumors, Progression
Laser Ablation After Stereotactic Radiosurgery
The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool.
- Conditions
- Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
- Trial name
- LAASR (NCT01651078)
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Monteris Medical
Seminoma, Stage II
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb < 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of…
- Trial name
- EDEN (NCT05529251)
- Testing
- Radiotherapy boost, Carboplatin AUC7, 3 cycles of EP
- Where
- 15 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Leon Berard
Liver Metastases, Hepatic Metastases
Therapeutic Efficacy and Safety of Ultrasound-Guided Microwave Ablation for Hepatic Metastatic Nodules
The liver is one of the most common organs where cancer cells spread (metastasize) from other parts of the body, especially from gastrointestinal cancers such as colorectal cancer.
- Conditions
- Liver Metastases, Hepatic Metastases, Secondary Malignant Neoplasm of Liver, Colorectal Cancer Metastatic
- Trial name
- NCT07871253
- Testing
- Ultrasound-Guided Microwave Ablation
- Volunteers
- 30 people
- Sponsor
- Assiut University
Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study
This study evaluates the safety and efficacy of Befotertinib combined with Bevacizumab as a first-line treatment for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) accompanied by brain or…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases
- Trial name
- Better Brain (NCT06728865)
- Testing
- The treatment regimen is Befotertinib combined with Bevacizumab.
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Li-kun Chen
Cavernous Angioma, Familial, Cerebral Cavernous Malformations
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches.
- Conditions
- Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
- Trial name
- NCT01764529
- Where
- 7 sites in United States
- Volunteers
- 789 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression…
- Trial name
- NCT02921737
- Testing
- TAS-102
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Breast Cancer
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
In the phase I part, to determine the recommended doses (RD) and dosing regimens of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive…
- Trial name
- NeoB-Cap1 (NCT06247995)
- Testing
- [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine
- Where
- 28 sites in United States, Australia and 11 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Cancer
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy .
- Trial name
- NIVONASO-21 (NCT04875611)
- Testing
- Opdivo
- Where
- 4 sites in Poland
- Volunteers
- 32 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or…
- Trial name
- NCT06449209
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- BioNTech SE
Metastatic Breast Cancer
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer
The prognosis for patients with metastatic breast cancer has improved continuously. Systemic therapies alone are not able to cure the disease permanently.
- Trial name
- OLIGOMA (NCT04495309)
- Testing
- Metastases-directed Radiotherapy
- Where
- 14 sites in Germany
- Volunteers
- 87 people
- Sponsor
- University Hospital Schleswig-Holstein
Lung Cancer Metastatic
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2（VEGFR）、FGFR（fibroblast growth factor receptor）, platelet-derived growth factor…
- Trial name
- NCT03706287
- Testing
- anlotinib 8mg + AP/PC, anlotinib 10mg + AP/PC, anlotinib 12mg + AP/PC
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Prostatic Neoplasms
CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)
In this Phase I study safety of the combination of Docetaxel and Temsirolimus needs to be shown before the study can be expanded into a Phase II study to examine the activity of a safe combination of Temsirolimus and Docetaxel in…
- Trial name
- CEPTAS (NCT01206036)
- Testing
- Docetaxel, Temsirolimus
- Where
- 2 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Central European Society for Anticancer Drug Research
Breast Cancer
The Role of Diet and Lifestyle in Breast Cancer Survival
Diet has been found to influence hormone production and metabolism which in turn could affect the incidence of hormone related cancers.
- Trial name
- DietCompLyf (NCT00701584)
- Where
- United Kingdom
- Volunteers
- 3,390 people
- Sponsor
- University College London Hospitals
Prostate Cancer, Metastatic Prostate Cancer
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
This is an ambispective, multicenter, observational real-world registry of patients with synchronous de novo oligometastatic prostate cancer, defined as prostate cancer with up to 10 extraregional metastatic lesions diagnosed at…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Oligometastatic Prostate Cancer, Synchronous Oligometastatic Prostate Cancer
- Trial name
- SynSABR-PC (NCT07686016)
- Testing
- Definitive Prostate-Directed Radiotherapy, Metastasis-Directed Stereotactic Body Radiotherapy, Pelvic Lymph Node Irradiation
- Where
- Poland
- Volunteers
- 700 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.